Freeline to Present at 2023 Jefferies Healthcare Conference
02 Juin 2023 - 2:00PM
Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today
announced that its Chief Executive Officer Michael Parini will
present at the 2023 Jefferies Healthcare Conference being held in
New York on June 7-9, 2023.
The presentation will take place at 8 a.m. ET on June 9, 2023.
Senior management will also participate in one-on-one investor
meetings during the conference.
A live webcast of the presentation will be available on the
Investors section of Freeline’s website at www.freeline.life. An
archived replay of the webcast be available for approximately 90
days following the presentation.
About Freeline
TherapeuticsFreeline is a clinical-stage biotechnology
company focused on developing transformative gene therapies for
chronic debilitating diseases. Freeline uses its proprietary,
rationally designed AAV vector and capsid (AAVS3), along with novel
promoters and transgenes, to deliver a functional copy of a
therapeutic gene into human liver cells, thereby expressing a
persistent functional level of the missing or dysfunctional protein
into a patient’s bloodstream. The company is currently advancing
FLT201, a highly differentiated gene therapy candidate that
delivers a novel transgene, in a Phase 1/2 clinical trial in people
with Gaucher disease type 1. Freeline is headquartered in the UK
and has operations in the United States. For more information,
visit www.freeline.life or connect with Freeline on LinkedIn and
Twitter.
Media and Investor
Contact:Naomi Aokinaomi.aoki@freeline.lifeSenior Vice
President, Head of Investor Relations & Communications+ 1 617
283 4298
Freeline Therapeutics (NASDAQ:FRLN)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Freeline Therapeutics (NASDAQ:FRLN)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024